Last Updated: 04/06/07
Drug Development— Rapid Access to Intervention Development— for Academics and not-for-profits
http://dtp.nci.nih.gov/docs/raid/raid_index.html
Contact:
Coordinator, RAID Program
301 -496-8720, raid@dtpax2.ncifcrf.gov
Translating promising target-directed compounds into drugs for human use is an exacting task that requires very specific, interrelated activities. NCI supports this critical arm of drug development through a variety of initiatives, including DTP’s Rapid Access to Intervention Development (RAID) program.
RAID provides preclinical drug and biologic development resources to academic investigators who want to conduct their own clinical trials. Once an optimal compound is selected via R•A•N•D or another discovery path, RAID facilitates further preclinical development.
Since its inception in 1998, the RAID program has approved 104 projects, through which 13 small molecules and 11 biologic agents later entered clinical trials.
The goal of RAID is to provide clinical proof of principle that a new molecule or approach is a viable candidate for expanded clinical evaluation. Tasks supported by RAID include:
- Large-scale synthesis and formulation
- Pharmacology and toxicology
- In vivo screening
- Developmental tasks necessary to translate discoveries to the clinic
- Regulatory affairs, so that FDA requirements are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic
RAID is not a mechanism for obtaining grants. To access the services of the RAID program, academic researchers may submit applications twice yearly— February 1 and August 1. Submissions are reviewed by a panel of extramural experts who assess the strength of hypothesis, scientific novelty, and cost-benefit ratio of the project. Once a project is accepted, DTP provides drug development resources free of charge. The output of RAID activities will be both products and information made fully available to the originating investigator for support of an IND application and clinical trials.
